MA51681A - Anticorps humains contre l'hémagglutinine de la grippe - Google Patents

Anticorps humains contre l'hémagglutinine de la grippe

Info

Publication number
MA51681A
MA51681A MA051681A MA51681A MA51681A MA 51681 A MA51681 A MA 51681A MA 051681 A MA051681 A MA 051681A MA 51681 A MA51681 A MA 51681A MA 51681 A MA51681 A MA 51681A
Authority
MA
Morocco
Prior art keywords
human antibodies
antibodies against
influenza hemagglutinin
against influenza
hemagglutinin
Prior art date
Application number
MA051681A
Other languages
English (en)
Inventor
William Olson
Lisa A Purcell
Jonathan Viau
Original Assignee
Regeneron Pharma
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Regeneron Pharma filed Critical Regeneron Pharma
Publication of MA51681A publication Critical patent/MA51681A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/108—Orthomyxoviridae (F), e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/42—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum viral
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/734—Complement-dependent cytotoxicity [CDC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Communicable Diseases (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Emergency Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
MA051681A 2018-01-26 2019-01-24 Anticorps humains contre l'hémagglutinine de la grippe MA51681A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201862622480P 2018-01-26 2018-01-26

Publications (1)

Publication Number Publication Date
MA51681A true MA51681A (fr) 2021-05-05

Family

ID=66286952

Family Applications (1)

Application Number Title Priority Date Filing Date
MA051681A MA51681A (fr) 2018-01-26 2019-01-24 Anticorps humains contre l'hémagglutinine de la grippe

Country Status (17)

Country Link
US (1) US11780907B2 (fr)
EP (1) EP3743442A1 (fr)
JP (2) JP7372925B2 (fr)
KR (1) KR102820941B1 (fr)
CN (1) CN111670195B (fr)
AU (1) AU2019212480B2 (fr)
BR (1) BR112020014849A2 (fr)
CA (1) CA3088194A1 (fr)
CL (1) CL2020001884A1 (fr)
CO (1) CO2020009043A2 (fr)
EA (1) EA202091563A1 (fr)
IL (1) IL275884B2 (fr)
MA (1) MA51681A (fr)
MX (1) MX2020007772A (fr)
PH (1) PH12020551051A1 (fr)
SG (1) SG11202006379UA (fr)
WO (1) WO2019147867A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112022007923A2 (pt) * 2019-10-28 2022-07-26 Regeneron Pharma Anticorpo recombinante isolado ou fragmento de ligação ao antígeno deste, composição farmacêutica, molécula de polinucleotídeo, vetor, célula, e, método para prevenir, tratar ou melhorar pelo menos um sintoma da infecção por influenza
EP4126934A1 (fr) * 2020-04-01 2023-02-08 University of Rochester Anticorps monoclonaux contre l'hémagglutinine (ha) et la neuraminidase (na) des virus de la grippe h3n2
KR20230135569A (ko) * 2020-11-23 2023-09-25 비르 바이오테크놀로지, 인코포레이티드 인플루엔자 a 바이러스에 대한 항체
CA3256034A1 (fr) 2022-04-14 2023-10-19 Invisishield Technologies Ltd. Compositions pour prévenir ou traiter des infections par la grippe
KR102835659B1 (ko) * 2024-11-28 2025-07-24 주식회사 마크헬츠 인플루엔자 a형 바이러스 검출용 항체 및 이의 용도

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US6596541B2 (en) 2000-10-31 2003-07-22 Regeneron Pharmaceuticals, Inc. Methods of modifying eukaryotic cells
US20040101920A1 (en) 2002-11-01 2004-05-27 Czeslaw Radziejewski Modification assisted profiling (MAP) methodology
US7850962B2 (en) 2004-04-20 2010-12-14 Genmab A/S Human monoclonal antibodies against CD20
US8257740B1 (en) 2011-08-15 2012-09-04 Gp Medical, Inc. Pharmaceutical composition of nanoparticles
US8246995B2 (en) 2005-05-10 2012-08-21 The Board Of Trustees Of The Leland Stanford Junior University Hydrophobic nanotubes and nanoparticles as transporters for the delivery of drugs into cells
CA2608656A1 (fr) * 2005-05-16 2006-11-23 Morphotek, Inc. Vecteurs regules pour la selection de cellules presentnant des phenotypes specifiques
RS52176B (sr) 2006-06-02 2012-08-31 Regeneron Pharmaceuticals Inc. Antitela visokog afiniteta prema humanom il-6 receptoru
CA2663388C (fr) 2006-09-07 2017-01-17 Crucell Holland B.V. Molecules de liaison humaines capables de neutraliser le virus de la grippe h5n1 et leurs utilisations
EP1947423A1 (fr) 2007-01-16 2008-07-23 Sony Deutschland Gmbh Contrôleur sensible à la distance, à l'orientation et à la vitesse
CA2687147C (fr) 2007-05-11 2016-08-23 Temasek Life Sciences Laboratory Limited Proteines de liaison specifiques au sous-type h5 utiles pour le diagnostic et la surveillance de la grippe aviaire h5
AU2008297594B2 (en) 2007-09-13 2013-06-20 Temasek Life Sciences Laboratory Limited Monoclonal antibodies specific to hemagglutinin and neuraminidase from influenza virus H5-subtype or N1-subtype and uses thereof
JP5490695B2 (ja) 2007-09-13 2014-05-14 テマセック・ライフ・サイエンシズ・ラボラトリー・リミテッド インフルエンザウイルスｈ５亜型からのヘマグルチニンに特異的なモノクローナル抗体およびそれらの使用
MX2010006148A (es) 2007-12-06 2011-02-23 Dana Farber Cancer Inst Inc Anti-cuerpos contra el virus de la influenza y metodos de uso de los mismos.
AU2008349862B2 (en) 2008-02-05 2014-02-06 Temasek Life Sciences Laboratory Limited Binding protein and epitope-blocking ELISA for the universal detection of H5-subtype influenza viruses
WO2009121004A2 (fr) 2008-03-28 2009-10-01 Sea Lane Biotechnologies, Llc Molécules neutralisantes d'antigènes viraux
US8871207B2 (en) 2008-07-25 2014-10-28 Humabs, LLC Neutralizing anti-influenza A virus antibodies and uses thereof
ES2662519T3 (es) 2008-07-25 2018-04-06 Institute For Research In Biomedicine Anticuerpos neutralizantes contra el virus de la gripe A y usos de estos
CA2736799A1 (fr) 2008-08-25 2010-03-11 Burnham Institute For Medical Research Epitope conserve d'hemagglutinine, anticorps contre l'epitope et procedes d'utilisation
CN102292350A (zh) 2008-12-24 2011-12-21 淡马锡生命科学研究院有限公司 对来自甲型流感病毒血凝素的融合肽特异的单克隆抗体及其用途
EP2380976A4 (fr) 2008-12-25 2012-11-07 Univ Osaka Anticorps humain anti-virus de la grippe humaine
WO2010130636A1 (fr) 2009-05-11 2010-11-18 Crucell Holland B.V. Molécules de liaison humaines pouvant neutraliser le virus de la grippe h3n2 et leurs utilisations
CN102482345A (zh) 2009-05-13 2012-05-30 航道生物技术有限责任公司 针对流感病毒的中和分子
KR101747103B1 (ko) 2009-06-26 2017-06-14 리제너론 파마슈티칼스 인코포레이티드 천연 면역글로불린 포맷을 가지는 용이하게 분리된 이중특이성 항체
US10143186B2 (en) 2010-02-08 2018-12-04 Regeneron Pharmaceuticals, Inc. Common light chain mouse
US9573991B2 (en) 2010-03-08 2017-02-21 Celltrion, Inc. Human monoclonal antibodies derived from human B cells and having neutralizing activity against influenza A viruses
JP6050747B2 (ja) 2010-06-17 2016-12-21 トレリス バイオサイエンス リミテッド ライアビリティー カンパニー インフルエンザ受動免疫化に有用な抗体
US9534042B2 (en) 2010-09-03 2017-01-03 Fujita Health University Influenza virus-neutralizing antibody and screening method therefor
WO2012045001A2 (fr) 2010-09-30 2012-04-05 Vanderbilt University Anticorps dirigés contre le virus de la grippe, immunogènes et leurs utilisations
US8961978B2 (en) 2011-07-14 2015-02-24 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza A viruses of phylogenetic group 1 and phylogenetic group 2 and influenza B viruses
ITRM20110606A1 (it) 2011-11-16 2013-05-17 Ist Superiore Sanita Peptidi della lattoferrina per lo uso come inibitori ad ampio spettro dellainfezione da virus della influenza.
JP6325451B2 (ja) 2011-12-02 2018-05-16 アイム・セラピューティクス・べー・フェー Ａ型インフルエンザに特異的な抗体
CN104302321A (zh) 2011-12-05 2015-01-21 特瑞利斯生物科学有限责任公司 可用于被动流感免疫的抗体
KR102050615B1 (ko) 2012-03-08 2019-11-29 얀센 백신스 앤드 프리벤션 비.브이. 인플루엔자 b 바이러스들에 결합하고 중화할 수 있는 인간 결합 분자 및 그 용도
US9969794B2 (en) 2012-05-10 2018-05-15 Visterra, Inc. HA binding agents
AU2013345072B2 (en) 2012-11-13 2017-12-07 Genentech, Inc. Anti-hemagglutinin antibodies and methods of use
TWI635098B (zh) 2013-02-01 2018-09-11 再生元醫藥公司 含嵌合恆定區之抗體
KR20140118682A (ko) 2013-03-29 2014-10-08 (주)셀트리온 2 이상의 인플루엔자 ａ 바이러스 중화 결합 분자를 포함하는 조성물
JP6535675B2 (ja) 2013-10-02 2019-06-26 メディミューン，エルエルシー 抗ａ型インフルエンザ抗体の中和及びその使用
KR102344390B1 (ko) * 2014-02-04 2021-12-28 콘트라펙트 코포레이션 수동 인플루엔자 면역화에 유용한 항체, 및 이의 사용을 위한 조성물, 조합 및 방법
WO2015148806A1 (fr) 2014-03-27 2015-10-01 Genentech, Inc. Anticorps hémagglutinine dirigés contre le virus de la grippe b et méthodes d'utilisation
CN104031118B (zh) 2014-06-19 2016-04-13 天津大学 鼠多瘤病毒衣壳粒的新型亲和肽配基及其设计筛选方法
TWI702229B (zh) 2014-12-19 2020-08-21 美商再生元醫藥公司 流行性感冒病毒血球凝集素之人類抗體
US10435462B2 (en) 2015-03-31 2019-10-08 Viro Dynamics Corporation Hybrid influenza seed viruses, compositions thereof, and use thereof in the diagnosis or therapy of influenza
US11135282B2 (en) * 2015-04-08 2021-10-05 Dana-Farber Cancer Institute, Inc. Humanized influenza monoclonal antibodies and methods of use thereof
MX389708B (es) 2015-06-01 2025-03-20 Medimmune Llc Neutralizacion de moleculas de union anti-influenza y usos de las mismas.
WO2017192589A1 (fr) * 2016-05-02 2017-11-09 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Anticorps neutralisants dirigés contre la grippe ha, leur utilisation et leur identification
WO2020221450A1 (fr) 2019-04-30 2020-11-05 Humabs Biomed Sa Anticorps et méthodes de traitement d'une infection par la grippe a

Also Published As

Publication number Publication date
US11780907B2 (en) 2023-10-10
PH12020551051A1 (en) 2021-08-23
KR102820941B1 (ko) 2025-06-16
IL275884B2 (en) 2024-11-01
CL2020001884A1 (es) 2020-12-11
WO2019147867A9 (fr) 2019-11-07
BR112020014849A2 (pt) 2020-12-08
AU2019212480B2 (en) 2025-07-24
IL275884A (en) 2020-08-31
US20210371505A1 (en) 2021-12-02
CO2020009043A2 (es) 2020-07-31
WO2019147867A1 (fr) 2019-08-01
CN111670195A (zh) 2020-09-15
AU2019212480A1 (en) 2020-09-10
MX2020007772A (es) 2020-09-18
CA3088194A1 (fr) 2019-08-01
EA202091563A1 (ru) 2020-10-08
JP2023060018A (ja) 2023-04-27
JP2021511043A (ja) 2021-05-06
EP3743442A1 (fr) 2020-12-02
JP7372925B2 (ja) 2023-11-01
CN111670195B (zh) 2024-08-13
SG11202006379UA (en) 2020-07-29
KR20200115517A (ko) 2020-10-07
IL275884B1 (en) 2024-07-01

Similar Documents

Publication Publication Date Title
MA49043A (fr) Formulation stable d'anticorps
MA51681A (fr) Anticorps humains contre l'hémagglutinine de la grippe
EP3618871A4 (fr) Formulations d'anticorps anti-lag3 etco-formulations d'anticorps anti-lag3 et d'anticorps anti-pd-1
EP3700416A4 (fr) Capteurs d'analyte préconnectés
EP3635724A4 (fr) Techniques de suivi d'objet
MA43108A (fr) Anticorps neutralisant le virus syncytial respiratoire humain
EP3496753A4 (fr) Formulation d'anticorps anti-pd-1
EP3807318A4 (fr) Constructions d'anticorps multi-spécifiques
MA51903A (fr) Formulations d'anticorps b7-h4
EP3529009A4 (fr) Robot de suivi humain
MA54052A (fr) Formulation d'anticorps
EP3814507A4 (fr) Mutants d'hémagglutinine du virus de la grippe
MA54139A (fr) Formulation d'anticorps
EP3837286A4 (fr) Anticorps dirigés contre znt8 humain
MA55033A (fr) Formulation d'anticorps thérapeutique
EP3735987A4 (fr) Conjugué d'anticorps à base d'amanitine
EP3849612A4 (fr) Variants d'anticorps anti-vih 10-1074
MA54097A (fr) Anticorps anti-fn14 humain
MA53466A (fr) Formulation stable d'anticorps anti-osmr
EP3833691A4 (fr) Anticorps anti-pd-l1 humains
EP3870222A4 (fr) Anticorps anti-vih
EP3885362A4 (fr) Conjugué d'anticorps
MA47106A (fr) Formulations d'anticorps anti-tnf alpha
MA46642A (fr) Promédicaments d'inhibiteurs de la kallicréine
EP3805389A4 (fr) Anticorps anti-tlr7 humain